This article provides a research-focused literature overview of 5-amino-1mq capsules research for laboratory investigators and readers interested in the published science. Mention of “capsules” is included only as product-format context; the content below concentrates on the active compound, study themes, and the peer-reviewed literature. Visit the Peptide Titans homepage for site-level context: Peptide Titans.
What is 5‑Amino‑1MQ?
5‑Amino‑1MQ (5‑amino‑1‑methylquinolinium) is described in the biochemical and medicinal chemistry literature as a substrate‑mimetic inhibitor of nicotinamide N‑methyltransferase (NNMT). In published reports it is characterized as a small‑molecule NNMT inhibitor and is used as a laboratory tool compound to probe NNMT enzymology and downstream metabolic pathways.
How 5‑Amino‑1MQ Appears in the Published Literature
Published literature presents 5‑Amino‑1MQ primarily as a research reagent. Sources include medicinal chemistry studies reporting structure–activity relationships (SAR), in vitro target engagement, and cell‑based assays, as well as preclinical animal model experiments reported for mechanistic exploration. Review articles place 5‑Amino‑1MQ among NNMT inhibitor chemotypes under active investigation in basic research.
Major Study Areas and Model Types
Chemical discovery and structure–activity studies
Medicinal chemistry reports describe the N‑methylquinolinium scaffold, SAR campaigns, and selectivity testing versus related methyltransferases. Typical endpoints in these studies include inhibitory potency metrics (IC50/Ki) and chemical modifications informed by activity profiles.
Cellular and biochemical assays
Laboratory studies employ cultured cell systems and biochemical assays to measure NNMT enzymatic activity and metabolic readouts, including quantification of 1‑methyl nicotinamide (1‑MNA) as a proximal biochemical marker. Methods commonly reported include enzymatic inhibition curves, target‑engagement measurements, and targeted mass spectrometry for metabolites.
Preclinical animal models
Preclinical reports use rodent models for hypothesis‑driven mechanistic exploration. These studies are presented in the literature as exploratory research to probe biochemical pathways and are not clinical validation.
Mechanisms and Pathways Investigated
Researchers investigate mechanistic themes that link NNMT enzymology to broader metabolic networks. Recurring topics include:
- SAM (S‑adenosylmethionine) and NAD+ metabolism — NNMT catalyzes nicotinamide methylation to 1‑MNA, connecting methyl donor pools to NAD+‑related pathways.
- Polyamine flux and acetylation pathways — downstream effects on acetylation and polyamine metabolism are explored in some reports.
- Target engagement readouts — measurement of 1‑MNA and related metabolites serves as a biochemical marker of NNMT activity.
Key Terms and Study Terminology
Readers will commonly see the following technical terms in primary sources:
- IC50 / Ki — inhibitory potency metrics used in biochemical assays.
- Substrate‑mimetic / competitive inhibition — descriptors of inhibitor interactions with NNMT.
- 1‑MNA quantification — targeted assays or mass spectrometry to measure N‑methyl nicotinamide.
- SAR (structure–activity relationship) — medicinal chemistry analysis linking structural changes to activity.
- Caco‑2 permeability and other ADME assays — in vitro tests used to characterize membrane permeability and early pharmacokinetic properties in research settings.
Limits of the Current Research
Published literature on 5‑Amino‑1MQ is predominantly preclinical. Important limitations noted in source articles and reviews include:
- Model scope — much data derive from cell lines and rodent models; cross‑species and model translation can be variable.
- Chemotype variability — different NNMT inhibitor classes have distinct properties requiring careful comparison across chemotypes.
- Pharmacology and safety profiling — comprehensive pharmacokinetic and toxicology datasets for early inhibitors are limited in public literature.
- Mechanistic complexity — NNMT interfaces with methylation and NAD+ metabolism, making it challenging to disentangle direct enzymatic effects from downstream metabolic adaptations.
Why Research‑Only Language Matters
Research‑only phrasing preserves scientific accuracy and regulatory clarity. Primary sources use experimental descriptors, hypothesis generation, and model‑specific findings; adopting similar language in summaries avoids implying clinical efficacy, practical use instructions, or recommendations.
Product‑Format Context
Products containing 5‑Amino‑1MQ may be presented in formats such as capsules; this mention is product‑format context only and not an instruction or protocol. For information about Peptide Titans product listings and lab result transparency, see the Peptide Titans shop and lab results pages: Shop (Peptide Titans) and Lab Results (Peptide Titans).
Concluding Remarks and Recommended Reading
The peer‑reviewed literature positions 5‑Amino‑1MQ as a research tool within NNMT enzymology and preclinical investigation. It appears alongside other chemotypes in studies exploring mechanistic links between NNMT activity, methylation biology, and metabolic pathways. Readers seeking primary experimental details should consult the representative sources listed below.
Research‑use Product Reference
Research-use product reference: 5‑Amino‑1MQ is listed at Peptide Titans for laboratory research use only. Products are not for human consumption. See Peptide Titans product listings: https://peptidetitans.com/shop/ and Peptide Titans lab documentation: https://peptidetitans.com/lab-results/.
Research Sources
Primary references and representative source materials used to prepare this overview:
- https://pmc.ncbi.nlm.nih.gov/articles/PMC5826726/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC8337113/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC8956669/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC12467181/
Frequently Asked Questions
What does 5‑Amino‑1MQ target in laboratory studies?
Published research identifies 5‑Amino‑1MQ as an NNMT inhibitor used to study nicotinamide methylation and related metabolic pathways in biochemical and cell‑based assays.
Are studies on 5‑Amino‑1MQ clinical trials?
The cited literature is predominantly preclinical, including in vitro assays, medicinal chemistry reports, and animal model studies. These publications are exploratory and mechanistic rather than clinical trial reports.
What model systems do researchers use with 5‑Amino‑1MQ?
Common models reported in the literature include enzyme inhibition assays, cultured cell systems (for example, adipocytes or other cell lines), and rodent preclinical models used for mechanistic exploration.
Where can I find original research on 5‑Amino‑1MQ?
Peer‑reviewed journals and public repositories such as PubMed Central host primary medicinal chemistry papers and review articles describing experimental methods and findings; see the Research Sources section above for representative links.